GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gansu Longshenrongfa Pharmaceutical Industry Co Ltd (SZSE:300534) » Definitions » Beneish M-Score

Gansu Longshenrongfa Pharmaceutical Industry Co (SZSE:300534) Beneish M-Score : -3.06 (As of May. 27, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Gansu Longshenrongfa Pharmaceutical Industry Co Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.06 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Gansu Longshenrongfa Pharmaceutical Industry Co's Beneish M-Score or its related term are showing as below:

SZSE:300534' s Beneish M-Score Range Over the Past 10 Years
Min: -4.15   Med: -2.76   Max: 6.65
Current: -3.06

During the past 13 years, the highest Beneish M-Score of Gansu Longshenrongfa Pharmaceutical Industry Co was 6.65. The lowest was -4.15. And the median was -2.76.


Gansu Longshenrongfa Pharmaceutical Industry Co Beneish M-Score Historical Data

The historical data trend for Gansu Longshenrongfa Pharmaceutical Industry Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gansu Longshenrongfa Pharmaceutical Industry Co Beneish M-Score Chart

Gansu Longshenrongfa Pharmaceutical Industry Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.47 -2.89 -2.85 -3.42 -2.76

Gansu Longshenrongfa Pharmaceutical Industry Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.15 -3.42 -3.76 -2.76 -3.06

Competitive Comparison of Gansu Longshenrongfa Pharmaceutical Industry Co's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Gansu Longshenrongfa Pharmaceutical Industry Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gansu Longshenrongfa Pharmaceutical Industry Co's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gansu Longshenrongfa Pharmaceutical Industry Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Gansu Longshenrongfa Pharmaceutical Industry Co's Beneish M-Score falls into.



Gansu Longshenrongfa Pharmaceutical Industry Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Gansu Longshenrongfa Pharmaceutical Industry Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9822+0.528 * 0.9022+0.404 * 0.8436+0.892 * 1.0608+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.1223+4.679 * -0.10323-0.327 * 0.9855
=-3.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Total Receivables was ¥260 Mil.
Revenue was 254.914 + 267.744 + 220.834 + 295.149 = ¥1,039 Mil.
Gross Profit was 187.878 + 149.256 + 147.392 + 203.3 = ¥688 Mil.
Total Current Assets was ¥736 Mil.
Total Assets was ¥1,430 Mil.
Property, Plant and Equipment(Net PPE) was ¥444 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥519 Mil.
Total Current Liabilities was ¥543 Mil.
Long-Term Debt & Capital Lease Obligation was ¥113 Mil.
Net Income was 22.141 + 14.82 + 14.634 + 12.188 = ¥64 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = ¥0 Mil.
Cash Flow from Operations was 84.711 + 58.092 + 56.259 + 12.341 = ¥211 Mil.
Total Receivables was ¥250 Mil.
Revenue was 296.323 + 398.577 + 124.633 + 159.58 = ¥979 Mil.
Gross Profit was 193.872 + 239.107 + 64.568 + 87.434 = ¥585 Mil.
Total Current Assets was ¥674 Mil.
Total Assets was ¥1,272 Mil.
Property, Plant and Equipment(Net PPE) was ¥335 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥436 Mil.
Total Current Liabilities was ¥480 Mil.
Long-Term Debt & Capital Lease Obligation was ¥112 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(259.995 / 1038.641) / (249.547 / 979.113)
=0.250322 / 0.25487
=0.9822

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(584.981 / 979.113) / (687.826 / 1038.641)
=0.59746 / 0.662237
=0.9022

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (736.322 + 443.566) / 1430.016) / (1 - (673.721 + 334.931) / 1272.481)
=0.174913 / 0.207334
=0.8436

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1038.641 / 979.113
=1.0608

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 334.931)) / (0 / (0 + 443.566))
=0 / 0
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(519.01 / 1038.641) / (435.953 / 979.113)
=0.499701 / 0.445253
=1.1223

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((113.319 + 542.959) / 1430.016) / ((112.288 + 480.266) / 1272.481)
=0.458931 / 0.465668
=0.9855

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(63.783 - 0 - 211.403) / 1430.016
=-0.10323

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Gansu Longshenrongfa Pharmaceutical Industry Co has a M-score of -3.06 suggests that the company is unlikely to be a manipulator.


Gansu Longshenrongfa Pharmaceutical Industry Co Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Gansu Longshenrongfa Pharmaceutical Industry Co's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Gansu Longshenrongfa Pharmaceutical Industry Co (SZSE:300534) Business Description

Traded in Other Exchanges
N/A
Address
No. 10, Defence Road, Dingyuan Town, Gansu Province, Lanzhou, CHN, 730101
Gansu Longshenrongfa Pharmaceutical Industry Co Ltd is mainly engaged in the pharmaceutical business. It is engaged in the research and development of new drugs, traditional Chinese medicine processing and production. Its products portfolio includes Yuan Hu Zhitong Dripping Pills, Qiwei Wenyang Capsule and Xiaoshuan Tongluo Tablets. Its products are used to adjust gas, promote blood circulation, relieve pain, relieve cough, eliminate phlegm, relieve asthma, clear heat, and dispel dampness, among others.
Executives
Chen Yao Wu Executives
Zhang Jin De Director
Zhang Fan Executives
Kong Jian Feng Executives
Yue Qing Xin Supervisors
Kang Yong Hong Executives

Gansu Longshenrongfa Pharmaceutical Industry Co (SZSE:300534) Headlines

No Headlines